Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

ABSTRACT: In view of advances in early detection and treatment, the 5-year relative survival rate for all cancer patients combined is now approximately 66%. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2% annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20% to 40% of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ot

SUBMITTER: Travis LB 

PROVIDER: S-EPMC4568989 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature